NCT04524702 2026-01-23
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
Phase 2 Completed
Clinical Trials
14 trialsNCT04054362 2025-11-21
PINBALL
Barts & The London NHS Trust
Phase 2 Completed
NCT02030860 2025-07-25
A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT03138720 2025-06-13
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
HonorHealth Research Institute
Phase 2 Active not recruiting
NCT05365893 2025-04-16
PHL Treatment in Pancreatic Cancer
Fox Chase Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT03520790 2025-03-21
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT03519308 2024-03-15
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Terminated
NCT04617067 2024-03-06
Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer
Cancer Trials Ireland
Phase 2 Completed
NCT03415854 2023-12-15
NABPLAGEMD
HonorHealth Research Institute
Phase 2 Completed
NCT02930902 2023-02-09
Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03331562 2022-12-27
A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer
Translational Genomics Research Institute
Phase 2 Completed
NCT03883919 2022-10-05
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
Washington University School of Medicine
Phase 1 Completed
NCT03300921 2022-03-31
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Terminated
NCT01197664 2018-07-02
Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery
Wake Forest University Health Sciences
Phase 1 Terminated